We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    05578716
Previous Study | Return to List | Next Study

Growth, Allergy and Neurodevelopment in Infants on Hydrolysed Formula (GRANDIOSA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05578716
Recruitment Status : Recruiting
First Posted : October 13, 2022
Last Update Posted : October 13, 2022
Sponsor:
Collaborators:
Lund University
Arla Foods
Information provided by (Responsible Party):
Magnus Domellöf, Umeå University

Brief Summary:

Breastfeeding is the recommended diet for all infants during the first half of infancy and is associated with numerous health benefits. However, when breastfeeding is not possible, an infant formula is the only nutritive alternative. Formula-fed infants have a different growth pattern compared to breastfed infants. Studies have shown that the higher protein content in infant formula compared to breastmilk results in a more rapid weight gain and an increased risk of overweight and obesity in childhood. For this reason, both quantity and quality of protein in infant formulae have been optimized during the last decade, to better meet the needs of infants and to support growth close to that of breastfed infants.

Protein hydrolysis, a common modification of infant formulae, has originally been developed for treatment of cow's milk protein allergy. Certain hydrolysed formulae have been suggested to prevent atopic eczema when given to infants with a family history of allergic disease but as of yet, the allergy preventive effect in infants without increased risk of allergic disease has been little studied. Partially hydrolysed infant formulae have also been suggested to reduce common functional gastrointestinal symptoms in infants.

New protein hydrolysates are continually developed for use in infant formulae, with the aim of reducing allergenicity, while ensuring optimal growth and development of infants. It is important to study the effects on growth and health outcomes in infants who are fed formulae based on these newly developed hydrolysates as compared to those fed standard intact protein formulae or breastmilk.

The overall aims of the current study are to evaluate the effects of two new hydrolysates on growth, immunological biomarkers, neurodevelopment, protein metabolism and gut microbiota in a randomized, controlled clinical trial of healthy infants. In compliance with European Food Safety Authority (EFSA) regulations for novel infant formulas based on hydrolysed protein, the primary outcome is change in weight standard deviation score (SDS) from baseline until 5 months of age.


Condition or disease Intervention/treatment Phase
Infant Formula Dietary Supplement: Partially hydrolysed formula Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 312 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will be randomised to either standard formula or one of two partially hydrolysed study formulae. Included in the study will also be a group of breast-fed infants acting as reference group.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Each formula in the study will have the same packaging besides from colour coding (green, blue, yellow). None of the study personnel are aware of which colour represents which formulae during the course of the intervention.
Primary Purpose: Prevention
Official Title: GRANDIOSA - Growth, Allergy and Neurodevelopment in Infants on Hydrolysed Formula
Actual Study Start Date : October 3, 2022
Estimated Primary Completion Date : June 2026
Estimated Study Completion Date : June 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Study formula 1
Formula-fed intervention group randomised to one of two study formulae
Dietary Supplement: Partially hydrolysed formula
Partially hydrolysed formula

Experimental: Study formula 2
Formula-fed intervention group randomised to one of two study formulae
Dietary Supplement: Partially hydrolysed formula
Partially hydrolysed formula

No Intervention: Standard formula
Formula-fed control group randomised to standard formula
No Intervention: Breast feeding
Reference group with exclusively breast-fed infants



Primary Outcome Measures :
  1. Weight [ Time Frame: At 5 months of age ]
    Primary outcome is weight Standard Deviation Score (SDS) at the end of the intervention.


Secondary Outcome Measures :
  1. Length. [ Time Frame: At enrollment at 2 months of age and monthly during the intervention up to 5 months of age. ]
    Growth pattern during the course of the intervention measured by length in centimeters and SDS.

  2. Head circumference. [ Time Frame: At enrollment at 2 months of age and monthly during the intervention up to 5 months of age. ]
    Growth pattern during the course of the intervention measured by head circumference in centimeters and SDS.

  3. Body composition [ Time Frame: At 4 months of age ]
    Assessing differences in body composition between study groups using fat percentage as measured by PeaPod (Pletysmography).

  4. Gastrointestinal tolerance. [ Time Frame: At enrollment at 2 months of age and during the intervention up to 5 months of age. ]
    Gastrointestinal tolerance using diary for information about stool frequency and consistency (in four grades from diarrhea to hard stools) in combination with questionnaire filled in by the parents based on Rome IV criteria for functional gastrointestinal disorders.

  5. Gastrointestinal immunology. [ Time Frame: At enrollment at 2 months of age and during the intervention up to 5 months of age. ]
    Markers of gastrointestinal immune activation using analysis of calprotectin, eosinophilic derived neurotoxin and secretory Immunoglobulin A (IgA) in fecal samples.

  6. Eczema severity, parent report. [ Time Frame: At enrollment at 2 months of age and during the intervention up to 5 months of age. ]
    Parents will fill in the Patient-Oriented Eczema Measure (POEM) score monthly during the intervention.

  7. Eczema severity, clinical assessment. [ Time Frame: At enrollment at 2 months of age and during the intervention up to 5 months of age. ]
    Excema severity is assessed at every study visit using the Eczema Area and Severity Index (EASI).

  8. Allergy. [ Time Frame: At enrollment at 2 months of age and at the end of the intervention at 5 months of age. ]
    Sensitization to cow's milk protein is assessed by Immunoglobulin E (IgE) in serum using ImmunoCap.

  9. Immunologic activity. [ Time Frame: At enrollment at 2 months of age and at the end of the intervention at 5 months of age. ]
    Blood cytokine patterns using Luminex: Interleukin 2 (IL-2) as a marker of general T cell activity. Interferon gamma (IFN-γ) as a marker of Helper T cells type 1 (Th1) activity. Interleukin 4 (IL-4) as a marker of helper T cells type 2 (Th2) activity. Tumor growth factor beta type 1 (TGF-β1) as a marker of T cell regulatory activity. Interleukin 17 A (IL17-A) as a marker of helper T cell type 17 (Th17) activity. C reactive protein (CRP) in plasma as a marker of general inflammatory response.

  10. Metabolic biomarkers in blood. [ Time Frame: At enrollment at 2 months of age and at the end of the intervention at 5 months of age. ]
    Insulin-like growth factor-1 (IGF-1). Insulin. C-peptide. Leptin. Leptin-receptor.

  11. Markers of protein metabolism. [ Time Frame: At enrollment at 2 months of age and at the end of the intervention at 5 months of age. ]
    Plasma amino acids. Blood urea nitrogen.

  12. Microbiota [ Time Frame: At enrollment at 2 months of age and during the intervention up to 5 months of age. ]
    Composition and diversity of the gut microbiota analysed in fecal samples. Bacterial DNA will be extracted and the V3-V4 region of the 16S rRNA gene will be amplified. Sequencing of all samples takes place on the Illumina MiSeq platform. Based on the results, we will also use metagenomic or Nanopore sequencing for deeper characterization of microbial composition and functions.

  13. Neurodevelopment at 6 months of age. [ Time Frame: At 6 months of age. ]
    Response in cerebral blood flow to visual and auditory stimuli as measured by functional near-infrared spectroscopy (fNIRS).

  14. Neurodevelopment at 12 months of age. [ Time Frame: At 12 months of age. ]
    Bayely scales of infant development (BSID) 3rd edition. Higher score is interpreted as better outcome.

  15. Neurodevelopment at 3 years of age. [ Time Frame: At 3 years of age ]
    Wechsler Preschool and Primary Scale of Intelligence (WIPPSI) 4th edition. Higher score is interpreted as better outcome.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   4 Weeks to 8 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy infants born at term
  • Birth weight 2500 to 4500 gram
  • Either exclusive breast-feeding (reference group) or exclusive formula-feeding (intervention and control group)

Exclusion Criteria:

  • Suspected or verified food allergy
  • Suspected or verified infant colic

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05578716


Contacts
Layout table for location contacts
Contact: Magnus Domellöf, MD, PhD +46907852128 magnus.domellof@umu.se

Locations
Layout table for location information
Sweden
Department of clinical science, Preventive Paediatrics, Lund university Recruiting
Malmö, Sweden, 20502
Contact: Pia Karlsland-Akeson, MD, PhD       pia.karlsland_akeson@med.lu.se   
Principal Investigator: Pia Karlsland-Akeson, MD, PhD         
Department of Clinical Sciences, Pediatrics, Umeå University Hospital Recruiting
Umeå, Sweden, 901 85
Contact: Magnus Domellöf, MD, PhD    0046 90 7852128    magnus.domellof@umu.se   
Principal Investigator: Magnus Domellöf, MD, PhD         
Sponsors and Collaborators
Umeå University
Lund University
Arla Foods
Investigators
Layout table for investigator information
Principal Investigator: Magnus Domellöf, MD, PhD Department of Clinical Sciences, Pediatrics, Umeå University Hospital
Layout table for additonal information
Responsible Party: Magnus Domellöf, Professor, Umeå University
ClinicalTrials.gov Identifier: NCT05578716    
Other Study ID Numbers: 20210707401
First Posted: October 13, 2022    Key Record Dates
Last Update Posted: October 13, 2022
Last Verified: October 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Magnus Domellöf, Umeå University:
Infant nutrition
Food hypersensitivity
Dermatitis, Atopic
Protein hydrolysates
Spectroscopy, Near-Infrared
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypersensitivity
Immune System Diseases